Evidence map›Paper›PMID 40588549›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus.

Trupti N Prasad, Sandeep Singh Flora, Sanjay K Bhadada, Urmila Yadav, Rimesh Pal

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Recent Updates on Diabetes and Bone.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Trupti N PrasadDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 160012.
Sandeep Singh FloraStaff Clinic, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 160012.
Sanjay K BhadadaDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 160012.
Urmila YadavDivision of Neonatology, Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 160012.
Rimesh PalDepartment of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 160012. rimesh.ben@gmail.com.

Funding

Endocrine Society of India RG1Indian Society for Bone and Mineral Research 2022
6 · The paper itself

Abstract

Zoledronate, denosumab and teriparatide improve Falls Risk Assessment Score (FRAS) and reduce the number of participants experiencing falls over the last 12 months when administered over a period of 72 weeks to postmenopausal women with type 2 diabetes mellitus at a high risk of fragility fractures. PURPOSE: Type 2 diabetes mellitus (T2D) increases the risk of falls, which also exacerbates the risk of fragility fractures. We aimed at exploring the effects of anti-osteoporotic therapies (zoledronate, denosumab or teriparatide) on the risk of falls in postmenopausal women with T2D.

methodsWe performed an exploratory analysis of a randomized clinical pilot trial primarily designed to compare the efficacy of zoledronate, denosumab, or teriparatide in T2D (CTRI/2022/02/039978). Postmenopausal women (≥ 50 years) with T2D and high risk of fragility fractures were randomized to receive zoledronate (5 mg annually), denosumab (60 mg bi-annually), teriparatide (20 mcg daily) or only standard of care (calcium and cholecalciferol) for 72 weeks. The risk of falls was assessed using FRAS (Falls Risk Assessment Score) questionnaire at baseline and 72 weeks.

results129 postmenopausal women were randomized to one of the four treatment arms (mean age 64.2 ± 6.7 years). The baseline characteristics including FRAS were matched between four arms. At 72 weeks, all three interventions led to a significant reduction in FRAS (p = 0.002 for teriparatide, p = 0.004 for zoledronate, p = 0.004 for denosumab). No improvement was observed in control arm (p = 0.875). The number of participants experiencing more than one fall in last 12 months reduced in teriparatide, zoledronate and denosumab arms, while it increased in control arm (between-group p = 0.033). Glycemic status, renal function, calcium and vitamin D status either remained unchanged over 72 weeks or did not correlate with change in FRAS.

conclusionsZoledronate, denosumab and teriparatide reduce the risk of falls that might contribute to their anti-fracture efficacy.

Indexed as

Accidental FallsBone Density Conservation AgentsDiabetes Mellitus, Type 2Osteoporosis, PostmenopausalAgedBone DensityDenosumabFemaleHumansMiddle AgedOsteoporotic FracturesPilot ProjectsRisk AssessmentTeriparatideZoledronic AcidBone Density Conservation AgentsDenosumabTeriparatideZoledronic AcidAnti-osteoporotic therapyFallsFalls Risk Assessment ScoreFRAS

Identifiers

PMID40588549

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.